Complement Therapeutics
Cell & Gene Therapy · Biotechnology
Overview
Redefining Complement Therapies. Complement Therapeutics is a clinical-stage biotechnology company advancing precision therapies for complement-mediated diseases.
Funding and backers
Backers
2
BioGeneration Ventures, CIC
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Nov 26, 2025
New executive Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer · complementtx.com
Dec 5, 2023
New executive Complement Therapeutics Appoints Dr. Matthias Hebben, as Chief Technology Officer · complementtx.com
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Search for: At SonomaBio we believe in balance. Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered…
Innorna is a clinical-stage biotechnology company engineering mRNA-based medicines to treat chronic diseases, power in vivo…
MediSix Therapeutics develops innovative T-cell therapies using its proprietary PEBL technology platform. An IASO Biotechnology subsidiary.
Next-generation CAR T-cell therapies engineered to disrupt the tumor microenvironment OUR MISSION CARTemis Therapeutics is a clinical-stage…
AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet…
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
CICVia a fund
BioGeneration VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Next Generation Complement Therapeutics Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook
Opportunities center on targeted complement inhibitors, biologics, small molecules, RNA and gene therapies for rare diseases across ophthalmology, hematology and immunology.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Next Generation Complement Therapeutic
Read more
Report
Complement Therapeutics Announces Completion of Cohort 2 Dosing and Favourable IDMC Recommendation to Proceed to High Dose and Expansion Cohorts in the Phase I/II Opti-GAIN Study
CTx001 is an investigational AAV gene therapy being developed for Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
The Independent Data Monitoring Committee (IDMC) identified
Read more
Report
Complement Therapeutics Announces Completion of Cohort 1 Dosing and Favourable Independent Data Monitoring Committee Recommendation in the Phase I/II Opti-GAIN Study for GA Secondary to AMD
Cohort 1 enrolment completed in the Company's first-in-human Opti-GAIN clinical trial of CTx001 in Geographic Atrophy (GA) secondary to AMD
The Independent Data Monitoring Committee (IDMC) has recommen
Read more
Report
Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD
CTx001 is an investigational AAV-based gene therapy designed to deliver mini-CR1, a potent mo
Read more
Report
Complement Therapeutics Receives UK CTA Approval to Advance CTx001 into Opti-GAIN Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways within the complement system
UK Clinical Trial Authorisation (CTA) approval enables initiation of the Phase I/II Opti-GAIN clini
Read more
Report
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pa
Read more
Report
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track
Read more
Report
Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer
Munich, Germany - 26th November 2024 -
Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr
Read more
Report
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Dr
Read more
Report
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) applicati
Read more
Report
Show more news